Big Phar­ma hits pause on tri­als in Rus­sia, Ukraine as they ramp up hu­man­i­tar­i­an aid

Phar­ma com­pa­nies across the board are ral­ly­ing to pro­vide hu­man­i­tar­i­an aid amid a bloody war in Ukraine that’s tak­en the lives of at least hun­dreds of civil­ians.

Yet as clin­i­cal tri­als re­main un­der threat of dis­rup­tion and a cor­po­rate ex­o­dus out of Rus­sia con­tin­ues, all the signs point to sig­nif­i­cant chal­lenges ahead for Big Phar­ma.

Ru­ud Dob­ber, head of As­traZeneca’s bio­phar­ma­ceu­ti­cals busi­ness unit, re­vealed ear­li­er this week at Cowen’s Health­care Con­fer­ence that the phar­ma gi­ant has sus­pend­ed en­roll­ment of some clin­i­cal tri­als in Ukraine and Rus­sia as the war en­ters its 13th day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER